A detailed history of Woodline Partners LP transactions in Savara Inc stock. As of the latest transaction made, Woodline Partners LP holds 2,305,195 shares of SVRA stock, worth $6.96 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
2,305,195
Holding current value
$6.96 Million
% of portfolio
0.09%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.96 - $5.07 $9.13 Million - $11.7 Million
2,305,195 New
2,305,195 $9.77 Million
Q1 2021

May 17, 2021

SELL
$1.17 - $2.33 $438,637 - $873,526
-374,904 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$1.0 - $1.47 $218,690 - $321,474
-218,690 Reduced 36.84%
374,904 $431,000
Q3 2020

Nov 16, 2020

BUY
$1.09 - $2.21 $245,439 - $497,634
225,174 Added 61.12%
593,594 $647,000
Q2 2020

Aug 14, 2020

BUY
$1.8 - $3.05 $35,053 - $59,395
19,474 Added 5.58%
368,420 $917,000
Q1 2020

May 15, 2020

BUY
$1.91 - $4.08 $666,486 - $1.42 Million
348,946 New
348,946 $740,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $344M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.